Literature DB >> 19502174

Primary sclerosing cholangitis in Turkish patients: characteristic features and prognosis.

Hilmi Ataseven1, Erkan Parlak, Ilhami Yüksel, Omer Başar, Ibrahim Ertuğrul, Nurgül Saşmaz, Burhan Sahin.   

Abstract

BACKGROUND: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by destruction and fibrosis of the bile ducts. This study aimed to demonstrate the hepatic and extrahepatic characteristic findings and prognostic outcomes of Turkish patients with PSC.
METHODS: The medical records of 35 consecutive patients with PSC from January 1988 to June 2007 were recorded prospectively. From the time of diagnosis, clinical features and laboratory data were collected.
RESULTS: The mean age of the 35 patients was 41.69 years (range 15-80 years) at the time of diagnosis; 14 (40%) were female, and 21 (60%) were male. The mean duration of follow-up was 58.86 months (1-180 months). Twenty (57.1%) of the patients with PSC were asymptomatic and 22 (62.9%) had inflammatory bowel disease. At the time of diagnosis, 20 (57.1%) of the patients had both intra- and extra-hepatic PSC. Twenty-one (60%) of the patients, who had undergone ERCP for stent placement, had dominant bile duct stenosis. Cholangiocarcinoma was found in 2 (5.7%) of the patients and cirrhosis was detected in 7 (20%); 5 (14.3%) underwent liver transplantation. The median follow-up time after liver transplantation was 23 months and all are still alive. Six (17.1%) patients died.
CONCLUSIONS: PSC has a clinical course varied from advanced liver disease requiring liver transplantation within a short time to being asymptomatic for decades. The prognosis of Turkish patients with PSC is also disappointing as described in other studies.

Entities:  

Mesh:

Year:  2009        PMID: 19502174

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  5 in total

Review 1.  Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current Knowledge of Pathogenesis and Therapeutics.

Authors:  Ji-Won Park; Jung-Hee Kim; Sung-Eun Kim; Jang Han Jung; Myoung-Kuk Jang; Sang-Hoon Park; Myung-Seok Lee; Hyoung-Su Kim; Ki Tae Suk; Dong Joon Kim
Journal:  Biomedicines       Date:  2022-05-31

2.  Overlap of primary biliary cirrhosis and primary sclerosing cholangitis - a rare coincidence or a new syndrome.

Authors:  Arun Jeevagan
Journal:  Int J Gen Med       Date:  2010-05-26

3.  Cholangiocarcinoma Secondary to Primary Sclerosing Cholangitis in Explanted Livers: A Single-Center Study in the South of Iran.

Authors:  Bita Geramizadeh; Roshanak Ghavvas; Kurosh Kazemi; Alireza Shamsaeefar; Saman Nikeghbalian; Seyed-Ali Malekhosseini
Journal:  Hepat Mon       Date:  2015-12-27       Impact factor: 0.660

4.  Clinical Features and Outcomes of Primary Sclerosing Cholangitis in the Highly Admixed Brazilian Population.

Authors:  Mateus Jorge Nardelli; Paulo Lisboa Bittencourt; Guilherme Grossi Lopes Cançado; Luciana Costa Faria; Cristiane Alves Villela-Nogueira; Vivian Rotman; Eliabe Silva de Abreu; Fernanda Maria Farage Osório; Andreia Silva Evangelista; Liliana Sampaio Costa Mendes; Daniel Ferraz de Campos Mazo; Elodie Bonfim Hyppolito; Adrielly de Souza Martins; Liana Codes; Izabelle Venturini Signorelli; Geisa Perez Medina Gomide; Luciana Agoglia; Claudia Alexandra Pontes Ivantes; Valéria Ferreira de Almeida E Borges; Gabriela Perdomo Coral; Rosamar Eulira Fontes Rezende; Maria Lucia Gomes Ferraz; Debora Raquel Benedita Terrabuio; Eduardo Luiz Rachid Cançado; Claudia Alves Couto
Journal:  Can J Gastroenterol Hepatol       Date:  2021-11-10

5.  Clinical guidelines for primary sclerosing cholangitis 2017.

Authors:  Hiroyuki Isayama; Susumu Tazuma; Norihiro Kokudo; Atsushi Tanaka; Toshio Tsuyuguchi; Takahiro Nakazawa; Kenji Notohara; Suguru Mizuno; Nobuhisa Akamatsu; Masahiro Serikawa; Itaru Naitoh; Yoshiki Hirooka; Toshifumi Wakai; Takao Itoi; Tomoki Ebata; Shinji Okaniwa; Terumi Kamisawa; Hiroki Kawashima; Atsushi Kanno; Keiichi Kubota; Masami Tabata; Michiaki Unno; Hajime Takikawa
Journal:  J Gastroenterol       Date:  2018-06-27       Impact factor: 7.527

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.